PYC Physiomics Plc

TIDMPYC

Physiomics PLC

02 March 2022

2 March 2022

Physiomics plc

("Physiomics") or ("the Company")

Contract award

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a contract by new client, Ankyra Therapeutics ("Ankyra"). Ankyra is a Boston-based biotech focused on improving both the safety and efficacy of cancer treatment by using their proprietary anchored immunotherapy platform. Ankyra recently announced a successful US$45 million Series B funding round to finance its lead molecule, ANK-101, through Phase 1 clinical trials and has an emerging pipeline of additional immunotherapy-based programs. Physiomics will be supporting Ankyra with modelling and simulation of ANK-101 in immune-oncology settings in support of its early development.

Physiomics CEO, Dr Jim Millen, commented : "We are delighted to have been selected by Ankyra Therapeutics as its partner for this modelling and simulation project focused on exciting new molecule ANK-101 and look forward to working with its talented team."

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour(TM) technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUPUCGWUPPPGG

(END) Dow Jones Newswires

March 02, 2022 02:01 ET (07:01 GMT)

Physiomics (LSE:PYC)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024

Physiomics (LSE:PYC)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024